Skip to main content

Table 3 Cluster association with the pathologic T stage

From: Immune landscape of human prostate cancer: immune evasion mechanisms and biomarkers for personalized immunotherapy

Cluster

Number of patients

T1

T2

T3

T4

Fisher exact p-value

Cluster 1

127

0 (0%)

51 (40.16%)

74 (58.27%)

2 (1.57%)

7.68E-01

Cluster 2

44

0 (0%)

23 (52.27%)

21 (47.73%)

0 (0%)

1.38E-01

Cluster 3

51

0 (0%)

9 (17.65%)

37 (72.55%)

5 (9.80%)

1.93E-03

Cluster 4

56

0 (0%)

16 (28.57%)

39 (69.64%)

1 (1.79%)

4.00E-01

Cluster 5

43

0 (0%)

19 (44.19%)

23 (53.49%)

1 (2.33%)

6.19E-01

Cluster 6

48

0 (0%)

16 (33.33%)

32 (66.67%)

0 (0%)

6.34E-01

Cluster 7

28

0 (0%)

15 (53.57%)

12 (42.86%)

1 (3.57%)

1.42E-01

Cluster 8

28

0 (0%)

8 (28.57%)

19 (67.86%)

1 (3.57%)

4.70E-01

Total

425

0 (0%)

183 (43.06%)

256 (60.24%)

12 (2.82%)

Â